ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) approved by the FDA to treat patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and the only approved inhibitor to successfully target BCR-ABL kinase T315I mutation in CML [181].